After a horror 2025, CSL Ltd (ASX: CSL) shares are rebounding in 2026. Here are three reasons the ASX biotech giant could ...

CSL Limited trades at a decade-low P/E, despite ongoing revenue and profit growth, presenting significant upside potential. Learn more about CMXHF stock here.

Amid trashed valuations, investors await for signs of life for healthcare stocks in the February profit-reporting season.

CSL says plasma donors can earn up to $100 per donation and as much as $750 per month. Here’s how it works and what to watch ...

I think CSL Ltd (ASX: CSL) shares are two more ASX 200 companies that are cheap buys at their current share prices.

Australia’s largest drugmaker CSL Ltd. is committing roughly $1.5 billion to expand its US manufacturing footprint, joining a wave of pharmaceutical giants doubling down on American production. The ...

Amid uncertainty for its vaccine division, CSL is growing the footprint of its bread-and-butter plasma therapies business by pledging a capital investment of about $1.5 billion for U.S.-based ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company announced in August ...

Netflix is the same stock it was on Friday, trading for the same valuation. Only the per-share price has changed. After close of trading on Friday, Netflix's 10-for-1 stock split, first announced two ...

CSL Ltd. plunged to the lowest in almost seven years after Australia’s biggest drugmaker postponed plans to spin off its vaccines business, as falling US flu immunizations deepen concern over a ...

Setting new standards in responsible innovation, CSL's Broadmeadows facility blends Pharma 4.0™ principles with sustainable design to transform plasma manufacturing Purpose-built to optimise the ...

CSL Ltd (ASX: CSL) shares have had a rough run this year. The biotech giant ended last week at $212.47, meaning its share price has tumbled about 28% over the past year. For a company long viewed as ...